Home › Compare › NILIF vs ABBV
NILIF yields 477.51% · ABBV yields 3.06%● Live data
📍 NILIF pulled ahead of the other in Year 1
Combined, NILIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NILIF + ABBV for your $10,000?
Surge Battery Metals Inc., an exploration stage company, engages in the acquisition, exploration, and development of mineral properties in North America. It focuses on gold, copper, lead, zinc, silver, cobalt, nickel, and precious metals. The company has an option to acquire 60% interests in two principal cobalt properties, including the Teledyne Cobalt property and the Glencore Bucke Cobalt property located in Ontario, Canada; and holds interest in the Nevada North lithium project that comprises of 154 mineral claims covering an area of approximately 794 hectares. It also has an option to acquire a 100% interest in the Quatse Lake property comprising four mineral claims covering an area of 1,786 hectares located in British Columbia; a 80% interest in the San Emidio Desert Lithium project comprising 35 mineral claims that covers an area of 2800 acres located to the North East of Reno, Nevada; and a 80% interest in the Nickel project located in British Columbia. The company was formerly known as Copper Creek Gold Corp. and changed its name to Surge Exploration Inc. in April 2018. Surge Battery Metals Inc. was incorporated in 1987 and is headquartered in Vancouver, Canada.
Full NILIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.